Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.
Polyclonal Antibodies Market Growth Potential: How Will Market Size Change Through 2030?
The market for polyclonal antibodies has experienced robust expansion in recent years, with projections indicating an increase from $1.48 billion in 2025 to $1.58 billion in 2026, reflecting a compound annual growth rate (CAGR) of 6.4%. This historical growth has been largely driven by a growing need for immunoassays, the widespread use of polyclonal antibodies in research settings, an expanding biotechnology industry, heightened academic research efforts, and the ready availability of animal models for antibody generation.
The polyclonal antibodies market is anticipated to experience robust expansion over the coming years. By 2030, it is projected to reach a valuation of $2.1 billion, reflecting a compound annual growth rate (CAGR) of 7.3%. This upward trajectory in the forecast period is driven by the broadening of precision medicine efforts, a surge in therapeutic antibody uses, innovations in antibody manufacturing, enhanced funding for diagnostics exploration, and heightened partnerships between pharmaceutical firms and research institutions. Key developments shaping this period encompass sophisticated methods for producing polyclonal antibodies, specialized services for custom antibody creation, their growing adoption in diagnostic tools, a rise in therapeutic research pursuits, and an increase in cooperative ventures between academic and pharmaceutical research groups.
Download A Free Sample Report For Comprehensive Market Insights:
Polyclonal Antibodies Market Demand Drivers Creating New Revenue Opportunities
The anticipated rise in cancer incidence is set to drive expansion in the polyclonal antibodies market moving forward. Cancer encompasses a range of disorders marked by uncontrolled cell growth and multiplication, resulting in tissue harm and possible spread to other parts of the body, while continuing to be a leading cause of illness and death globally. The growing number of cancer cases is influenced by factors including aging populations, modifications in lifestyle, and contact with environmental elements. Polyclonal antibodies play a key role in cancer research and treatment through applications such as detecting biomarkers, performing immunohistochemistry, conducting targeted therapy, and enabling immunotherapy, thereby enhancing diagnostic accuracy, treatment effectiveness, and patient results. As an example, in February 2024, data from the World Health Organization, an intergovernmental entity headquartered in Switzerland, indicated that more than 35 million new cancer cases are expected by 2050, reflecting a 77 percent rise from the roughly 20 million cases estimated in 2022. Consequently, the growing prevalence of cancer is fueling progress in the polyclonal antibodies market.
Polyclonal Antibodies Market Segment Landscape And Growth Potential
The polyclonal antibodies market covered in this report is segmented –
1) By Product Type: Primary Antibody, Secondary Antibody
2) By Source: Rabbits, Goats, Sheep, Other Sources
3) By Application: Research, Diagnostics, Therapy
4) By End-User: Academic and Research Center , Pharmaceutical and Biotechnology Companies, Diagnostic Centers , Hospitals
Subsegments:
1) By Primary Antibody: Immunoglobulin G (IgG), Immunoglobulin M (IgM), Immunoglobulin A (IgA), Immunoglobulin E (IgE)
2) By Secondary Antibody: Anti-Mouse IgG, Anti-Rabbit IgG, Anti-Goat IgG, Other Secondary Antibodies
Polyclonal Antibodies Market Trends Driving Strategic Industry Expansion
Market leaders within the polyclonal antibodies industry are placing strong emphasis on creating next-generation solutions, particularly hyperimmune antibody therapies, as a means to boost patient recovery rates, lower the risk of serious adverse events, and strengthen immune defenses. These hyperimmune treatments utilize polyclonal antibodies sourced from plasma donors possessing elevated neutralizing antibody levels, thereby offering tailored immune defense against viral pathogens. As a concrete example, SAB Biotherapeutics, a biotechnology firm based in the United States, revealed in April 2023 encouraging Phase 3 clinical data for its product SAB-185, a fully human polyclonal antibody therapy intended for individuals with a high probability of severe COVID-19 outcomes. By efficiently neutralizing SARS-CoV-2, SAB-185 was found to be both safe and effective, underscoring the capability of polyclonal antibody strategies to enhance treatment results for at-risk patient groups.
Polyclonal Antibodies Market Competitive Landscape: Who Are The Leading Companies?
Major companies operating in the polyclonal antibodies market are Abcam plc, GenScript Biotech Corporation, Merck KGaA, Thermo Fisher Scientific Inc., Becton Dickinson and Company, BioLegend Inc., Bio-Rad Laboratories Inc., Cell Signaling Technology Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Creative Diagnostics, Agilent Technologies, Analytik Jena GmbH, Atlas Antibodies, Danaher Corporation, DC Biosciences Ltd., ImmonoPresice Antibodies Ltd, Fujirebio, Omega BioTek Inc., Abnova Corporation, Santa Cruz Biotechnology Inc., Enzo Life Sciences Inc., Rockland Immunochemicals Inc., IGY Life Sciences, Genway Biotech, Good Biotech, Gallus Immunotech Inc., BioGenes GmbH, Capralogics Inc., Bio X Cell
Access The Complete Polyclonal Antibodies Market Report:
Polyclonal Antibodies Market Largest Region: Which Geography Holds The Highest Market Share?
North America was the largest region in the polyclonal antibodies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global polyclonal antibodies market size forecast period. The regions covered in the polyclonal antibodies market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model